Patents by Inventor Yaron Hakak
Yaron Hakak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9017949Abstract: The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.Type: GrantFiled: September 21, 2005Date of Patent: April 28, 2015Assignee: Arena Pharmacueticals, Inc.Inventors: James N. Leonard, Yaron Hakak
-
Publication number: 20140255310Abstract: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.Type: ApplicationFiled: February 13, 2014Publication date: September 11, 2014Applicant: ARENA PHARMACEUTICALS, INC.Inventors: Yaron Hakak, David J. Unett, Joel Gatlin, Chen W. Liaw
-
Patent number: 8691498Abstract: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.Type: GrantFiled: August 29, 2006Date of Patent: April 8, 2014Assignee: Arena Pharmaceuticals, Inc.Inventors: Yaron Hakak, David J. Unett, Joel Gatlin, Chen W. Liaw
-
Publication number: 20110177612Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: September 13, 2010Publication date: July 21, 2011Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz
-
Publication number: 20100331238Abstract: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-1 expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis.Type: ApplicationFiled: August 29, 2006Publication date: December 30, 2010Inventors: Yaron Hakak, David J. Unett, Joel Gatlin, Chen W. Liaw
-
Patent number: 7829298Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: GrantFiled: August 31, 2004Date of Patent: November 9, 2010Assignee: Arena Pharmaceuticals, Inc.Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel T. Connolly, Huong T. Dang, Bryan J. Choi, James N. Leonard, Yaron Hakak, Chen W. Liaw, Dominic P. Behan, Derek T. Chalmers, Michael R. Lerner, Kevin P. Lowitz
-
Publication number: 20100093604Abstract: The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound.Type: ApplicationFiled: September 21, 2005Publication date: April 15, 2010Applicant: Arena Pharmaceuticals, Inc.Inventors: James N. Leonard, Yaron Hakak
-
Publication number: 20070079392Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: November 22, 2006Publication date: April 5, 2007Applicant: Arena Pharmaceuticals, Inc.Inventors: Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz, David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly
-
Publication number: 20050154029Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: August 31, 2004Publication date: July 14, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin Lowitz
-
Patent number: 6902902Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: GrantFiled: December 6, 2002Date of Patent: June 7, 2005Assignee: Arena Pharmaceuticals, Inc.Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel T. Connolly, Yaron Hakak, Dominic P. Behan, Derek T. Chalmers
-
Publication number: 20050004178Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: July 23, 2004Publication date: January 6, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz
-
Publication number: 20040142377Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: December 6, 2002Publication date: July 22, 2004Applicant: Arena Pharmaceuticals, Inc.Inventors: David J. Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz